Clinical Trial 49481

Dallas, TX 75231


This study involves a drug called rimegepant. Rimegepant, brand name Nurtec, is currently approved by the FDA for the acute treatment in adult patients with migraine and for the preventive treatment in adult patients with episodic migraine. In this study, you will be entered into one of three study treatment groups: rimegepant dosed every other day alternating with matching placebo; rimegepant dosed daily; or placebo dosed daily. The goals of this study are: 1. To evaluate multiple dosing schedules of rimegepant compared to placebo as a preventative treatment for migraine. 2. To determine if multiple dosing schedules of rimegepant are well tolerated compared to placebo.

Participants must be:

·         Aged 18 years or above

·         Have a history of migraine headaches for at least one year

Qualified Participants May Receive:

If you qualify, you may receive investigational medication and study-related procedures from a local doctor. Reimbursement for time and travel related to study participation may be provided.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.